Supporting KIF18A’s therapeutic promise in genomically unstable cancers like triple-negative breast cancer and high-grade serous ovarian cancers, multiple KIF18A inhibitors have been developed and were recently reviewed by Chen and colleagues [147]. Here, KIF18A is linked to triple-negative breast carcinoma.